Biological E seeks DGCI approval to study Corbevax as booster dose
Corbevax is an RBD protein sub-unit vaccine currently under Phase 2/3 clinical trials in adults aged 18 years…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Oct 21
Corbevax is an RBD protein sub-unit vaccine currently under Phase 2/3 clinical trials in adults aged 18 years…
12 Oct 21
Merck’s regulatory submission for molnupiravir is based on positive results from the interim analysis of Phase 3 MOVe-OUT…
12 Oct 21
Gantenerumab is an investigational IgG1 antibody designed to block certain forms of amyloid beta and eliminate brain amyloid…
11 Oct 21
The company claims that Tavneos is the first orally-administered inhibitor of the complement 5a receptor to receive the…
11 Oct 21
Sandoz obtains rights to three established brands, including Zinnat, Zinacef and Fortum, which had combined sales of around…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Oct 21
The new facility includes drug substance manufacturing along with fill/finish and packaging
07 Oct 21
Voyager will receive an upfront payment of $30m, potential option exercise fees and milestone payments of up to…
06 Oct 21
The company’s submission of antibody cocktail is based on safety and efficacy data from the Phase 3 PROVENT…
05 Oct 21
The US FDA has granted BTD for Enhertu based on results from the DESTINY-Breast03 trial, in which Enhertu…
05 Oct 21
Cipla will expand access to Lilly’s diabetes drugs by leveraging its distribution capabilities and engaging its professionals